 Cory Christiansen
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Limbs | 31 | 2025 | 200 | 8.970 |
Why?
| | Walking | 36 | 2025 | 529 | 6.740 |
Why?
| | Gait | 24 | 2025 | 296 | 5.860 |
Why?
| | Amputees | 20 | 2025 | 96 | 5.820 |
Why?
| | Arthroplasty, Replacement, Knee | 17 | 2025 | 363 | 4.770 |
Why?
| | Exercise | 18 | 2025 | 2057 | 3.650 |
Why?
| | Exercise Therapy | 14 | 2025 | 443 | 3.580 |
Why?
| | Lower Extremity | 20 | 2025 | 427 | 3.220 |
Why?
| | Osteoarthritis, Knee | 15 | 2025 | 254 | 3.130 |
Why?
| | Veterans | 16 | 2025 | 1476 | 2.840 |
Why?
| | Tibia | 10 | 2024 | 178 | 2.540 |
Why?
| | Walk Test | 8 | 2024 | 76 | 2.280 |
Why?
| | Movement | 12 | 2025 | 278 | 2.210 |
Why?
| | Multiple Sclerosis | 6 | 2024 | 455 | 2.020 |
Why?
| | Middle Aged | 82 | 2025 | 33479 | 1.780 |
Why?
| | Activities of Daily Living | 7 | 2024 | 413 | 1.760 |
Why?
| | Aged | 68 | 2025 | 23961 | 1.760 |
Why?
| | Biomechanical Phenomena | 28 | 2025 | 810 | 1.750 |
Why?
| | Knee Joint | 13 | 2025 | 409 | 1.650 |
Why?
| | Muscle Strength | 9 | 2024 | 317 | 1.630 |
Why?
| | Accidental Falls | 5 | 2025 | 196 | 1.630 |
Why?
| | Femur | 7 | 2025 | 254 | 1.580 |
Why?
| | Osteoarthritis, Hip | 3 | 2024 | 45 | 1.520 |
Why?
| | Torso | 6 | 2021 | 33 | 1.520 |
Why?
| | Telerehabilitation | 4 | 2025 | 37 | 1.490 |
Why?
| | Resistance Training | 2 | 2024 | 164 | 1.460 |
Why?
| | Accelerometry | 7 | 2025 | 103 | 1.440 |
Why?
| | Self-Management | 3 | 2024 | 176 | 1.380 |
Why?
| | Disability Evaluation | 7 | 2023 | 290 | 1.320 |
Why?
| | Weight-Bearing | 9 | 2025 | 173 | 1.320 |
Why?
| | Recovery of Function | 11 | 2025 | 653 | 1.290 |
Why?
| | Parkinson Disease | 8 | 2025 | 493 | 1.260 |
Why?
| | Male | 76 | 2025 | 67762 | 1.200 |
Why?
| | Resilience, Psychological | 2 | 2021 | 128 | 1.180 |
Why?
| | Telemedicine | 4 | 2025 | 862 | 1.140 |
Why?
| | Self Efficacy | 4 | 2025 | 396 | 1.120 |
Why?
| | Prosthesis Design | 6 | 2025 | 327 | 1.120 |
Why?
| | Health Behavior | 5 | 2024 | 762 | 1.110 |
Why?
| | Humans | 110 | 2025 | 137585 | 1.090 |
Why?
| | Female | 75 | 2025 | 73304 | 1.070 |
Why?
| | Range of Motion, Articular | 13 | 2025 | 393 | 1.050 |
Why?
| | Muscle, Skeletal | 8 | 2025 | 1724 | 0.990 |
Why?
| | Task Performance and Analysis | 3 | 2024 | 183 | 0.990 |
Why?
| | Osseointegration | 10 | 2025 | 71 | 0.970 |
Why?
| | Cross-Sectional Studies | 18 | 2024 | 5472 | 0.950 |
Why?
| | Hip Joint | 6 | 2025 | 171 | 0.890 |
Why?
| | Joints | 1 | 2025 | 105 | 0.860 |
Why?
| | Single-Blind Method | 6 | 2024 | 282 | 0.860 |
Why?
| | Biofeedback, Psychology | 3 | 2025 | 37 | 0.850 |
Why?
| | Mobility Limitation | 3 | 2018 | 61 | 0.820 |
Why?
| | Aged, 80 and over | 21 | 2021 | 7635 | 0.810 |
Why?
| | Pelvis | 2 | 2020 | 102 | 0.730 |
Why?
| | Exercise Test | 9 | 2024 | 625 | 0.730 |
Why?
| | Physical Therapy Modalities | 5 | 2020 | 308 | 0.720 |
Why?
| | Arthroplasty, Replacement, Hip | 3 | 2024 | 177 | 0.710 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2021 | 7 | 0.710 |
Why?
| | Tobacco Smoking | 1 | 2021 | 25 | 0.700 |
Why?
| | Mechanical Phenomena | 1 | 2020 | 84 | 0.640 |
Why?
| | Prosthesis Implantation | 7 | 2024 | 153 | 0.610 |
Why?
| | Bone Density | 4 | 2018 | 489 | 0.610 |
Why?
| | Teriparatide | 1 | 2018 | 7 | 0.610 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2018 | 24 | 0.600 |
Why?
| | Adult | 31 | 2025 | 37929 | 0.600 |
Why?
| | Postural Balance | 5 | 2024 | 215 | 0.570 |
Why?
| | Patient Reported Outcome Measures | 4 | 2025 | 402 | 0.570 |
Why?
| | Hip | 3 | 2025 | 56 | 0.560 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 383 | 0.520 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 553 | 0.500 |
Why?
| | Feasibility Studies | 5 | 2025 | 956 | 0.490 |
Why?
| | Walking Speed | 1 | 2016 | 46 | 0.480 |
Why?
| | Behavior Therapy | 1 | 2018 | 264 | 0.470 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 655 | 0.460 |
Why?
| | Peripheral Vascular Diseases | 1 | 2015 | 103 | 0.440 |
Why?
| | Arthralgia | 1 | 2015 | 56 | 0.440 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 36 | 0.440 |
Why?
| | Quadriceps Muscle | 4 | 2024 | 133 | 0.430 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1431 | 0.430 |
Why?
| | Diabetic Angiopathies | 3 | 2019 | 259 | 0.390 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1477 | 0.340 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5778 | 0.310 |
Why?
| | Oxygen Consumption | 2 | 2025 | 696 | 0.300 |
Why?
| | Muscle Stretching Exercises | 1 | 2008 | 19 | 0.290 |
Why?
| | Ankle | 1 | 2008 | 60 | 0.280 |
Why?
| | Bone Density Conservation Agents | 3 | 2015 | 80 | 0.280 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2018 | 2531 | 0.280 |
Why?
| | Dependent Ambulation | 2 | 2019 | 10 | 0.280 |
Why?
| | Disease Progression | 2 | 2015 | 2757 | 0.270 |
Why?
| | Case-Control Studies | 5 | 2021 | 3556 | 0.260 |
Why?
| | Quality of Life | 5 | 2025 | 2892 | 0.250 |
Why?
| | Pilot Projects | 2 | 2024 | 1710 | 0.250 |
Why?
| | Phenotype | 1 | 2015 | 3196 | 0.250 |
Why?
| | Social Support | 2 | 2020 | 618 | 0.240 |
Why?
| | Patient Compliance | 3 | 2020 | 581 | 0.230 |
Why?
| | Kinetics | 2 | 2020 | 1670 | 0.230 |
Why?
| | Calcitonin | 2 | 2015 | 27 | 0.230 |
Why?
| | Synovitis | 2 | 2015 | 27 | 0.230 |
Why?
| | Multimorbidity | 1 | 2025 | 47 | 0.220 |
Why?
| | Pain Measurement | 3 | 2025 | 521 | 0.220 |
Why?
| | Treatment Outcome | 10 | 2025 | 10811 | 0.220 |
Why?
| | Postoperative Period | 3 | 2024 | 342 | 0.220 |
Why?
| | Retrospective Studies | 9 | 2024 | 15657 | 0.220 |
Why?
| | Cohort Studies | 4 | 2021 | 5742 | 0.210 |
Why?
| | Pain | 2 | 2024 | 756 | 0.210 |
Why?
| | Leg | 2 | 2016 | 236 | 0.210 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3284 | 0.210 |
Why?
| | Functional Laterality | 1 | 2024 | 223 | 0.210 |
Why?
| | Confidence Intervals | 2 | 2018 | 329 | 0.200 |
Why?
| | Patient Participation | 2 | 2024 | 420 | 0.200 |
Why?
| | Exercise Tolerance | 1 | 2025 | 279 | 0.200 |
Why?
| | Patient Satisfaction | 4 | 2021 | 660 | 0.190 |
Why?
| | Low Back Pain | 1 | 2024 | 108 | 0.190 |
Why?
| | Qualitative Research | 3 | 2025 | 1386 | 0.190 |
Why?
| | Regional Blood Flow | 1 | 2024 | 474 | 0.190 |
Why?
| | Peripheral Arterial Disease | 2 | 2019 | 475 | 0.190 |
Why?
| | Cumulative Trauma Disorders | 1 | 2022 | 42 | 0.190 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.180 |
Why?
| | CpG Islands | 1 | 2021 | 157 | 0.170 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 180 | 0.160 |
Why?
| | Smokers | 1 | 2021 | 145 | 0.160 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.160 |
Why?
| | Time Factors | 4 | 2025 | 6828 | 0.160 |
Why?
| | Decision Support Techniques | 1 | 2024 | 421 | 0.160 |
Why?
| | Double-Blind Method | 5 | 2019 | 1993 | 0.160 |
Why?
| | Cross-Over Studies | 2 | 2025 | 564 | 0.160 |
Why?
| | Mammography | 1 | 2000 | 154 | 0.160 |
Why?
| | Proof of Concept Study | 1 | 2019 | 78 | 0.150 |
Why?
| | Risk Factors | 6 | 2025 | 10388 | 0.150 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 48 | 0.150 |
Why?
| | Placebos | 1 | 2018 | 199 | 0.150 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 53 | 0.150 |
Why?
| | Patient Discharge | 1 | 2025 | 897 | 0.140 |
Why?
| | Heart Rate | 3 | 2025 | 822 | 0.140 |
Why?
| | High-Intensity Interval Training | 1 | 2018 | 25 | 0.140 |
Why?
| | Thiazolidinediones | 1 | 2018 | 137 | 0.140 |
Why?
| | Self-Assessment | 1 | 2018 | 72 | 0.140 |
Why?
| | Diet, Reducing | 1 | 1998 | 89 | 0.140 |
Why?
| | User-Computer Interface | 1 | 1998 | 159 | 0.140 |
Why?
| | Radiography | 3 | 2015 | 822 | 0.130 |
Why?
| | Feedback | 1 | 2017 | 173 | 0.130 |
Why?
| | Psychometrics | 1 | 2021 | 720 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2021 | 579 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 660 | 0.120 |
Why?
| | Ulna | 1 | 1996 | 27 | 0.120 |
Why?
| | Postmenopause | 1 | 1998 | 366 | 0.120 |
Why?
| | Radius | 1 | 1996 | 39 | 0.120 |
Why?
| | Posture | 1 | 2017 | 185 | 0.120 |
Why?
| | Amputation, Traumatic | 1 | 2016 | 20 | 0.120 |
Why?
| | Bone and Bones | 1 | 2018 | 317 | 0.120 |
Why?
| | DNA Methylation | 1 | 2021 | 643 | 0.120 |
Why?
| | Spine | 1 | 2017 | 173 | 0.120 |
Why?
| | Knee Prosthesis | 1 | 2015 | 27 | 0.120 |
Why?
| | Acceleration | 1 | 2015 | 35 | 0.120 |
Why?
| | Perception | 1 | 2018 | 359 | 0.120 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2012 | 42 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 331 | 0.110 |
Why?
| | Synovial Membrane | 1 | 2015 | 117 | 0.110 |
Why?
| | Cognition Disorders | 1 | 1998 | 496 | 0.110 |
Why?
| | Research Design | 2 | 2020 | 1139 | 0.110 |
Why?
| | Computer Simulation | 1 | 1998 | 978 | 0.110 |
Why?
| | Psychomotor Performance | 1 | 2016 | 309 | 0.110 |
Why?
| | Cartilage, Articular | 2 | 2015 | 311 | 0.110 |
Why?
| | Lumbar Vertebrae | 1 | 1996 | 246 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2018 | 546 | 0.110 |
Why?
| | Face | 1 | 2015 | 173 | 0.100 |
Why?
| | Motivation | 1 | 2018 | 570 | 0.100 |
Why?
| | Torque | 1 | 2013 | 84 | 0.100 |
Why?
| | Patient Safety | 1 | 2017 | 314 | 0.100 |
Why?
| | Osteoarthritis | 1 | 2015 | 185 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2009 | 307 | 0.100 |
Why?
| | Brain Injuries | 1 | 1998 | 494 | 0.100 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 293 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2828 | 0.100 |
Why?
| | Thigh | 1 | 2012 | 48 | 0.100 |
Why?
| | Peptide Fragments | 2 | 2015 | 706 | 0.100 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 108 | 0.090 |
Why?
| | Mass Screening | 1 | 2000 | 1287 | 0.090 |
Why?
| | Proteins | 1 | 1998 | 1009 | 0.090 |
Why?
| | Precision Medicine | 1 | 2015 | 429 | 0.090 |
Why?
| | United States | 3 | 2025 | 14841 | 0.090 |
Why?
| | Reference Values | 2 | 2013 | 816 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1622 | 0.090 |
Why?
| | Heart Failure | 1 | 2024 | 2236 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1024 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1329 | 0.080 |
Why?
| | Prognosis | 2 | 2015 | 4030 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1291 | 0.080 |
Why?
| | Metatarsophalangeal Joint | 1 | 2008 | 11 | 0.070 |
Why?
| | Models, Biological | 1 | 2015 | 1783 | 0.070 |
Why?
| | Ambulatory Care Facilities | 1 | 2010 | 232 | 0.070 |
Why?
| | Etidronic Acid | 1 | 2007 | 5 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2000 | 2253 | 0.070 |
Why?
| | Linear Models | 3 | 2013 | 849 | 0.070 |
Why?
| | Incidence | 1 | 2015 | 2804 | 0.070 |
Why?
| | Collagen Type I | 3 | 2015 | 136 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 2007 | 15 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2022 | 410 | 0.070 |
Why?
| | Hepatitis C | 1 | 2010 | 271 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2111 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3566 | 0.060 |
Why?
| | Body Mass Index | 1 | 2015 | 2389 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1316 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 129 | 0.060 |
Why?
| | Anger | 1 | 2025 | 60 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1864 | 0.060 |
Why?
| | Obesity | 1 | 1998 | 2992 | 0.060 |
Why?
| | Prospective Studies | 3 | 2015 | 7604 | 0.050 |
Why?
| | Collagen Type II | 2 | 2015 | 53 | 0.050 |
Why?
| | Canada | 1 | 2025 | 418 | 0.050 |
Why?
| | Osteoporosis | 1 | 2007 | 243 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 280 | 0.050 |
Why?
| | Foot | 1 | 2024 | 96 | 0.050 |
Why?
| | Antiparkinson Agents | 1 | 2022 | 27 | 0.050 |
Why?
| | Knee | 1 | 2023 | 68 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 106 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 57 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Biomarkers | 4 | 2015 | 4149 | 0.050 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 131 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2025 | 786 | 0.050 |
Why?
| | Goals | 1 | 2023 | 170 | 0.050 |
Why?
| | Administration, Oral | 2 | 2015 | 816 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 310 | 0.040 |
Why?
| | Sampling Studies | 1 | 2000 | 99 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2000 | 115 | 0.040 |
Why?
| | Physical Examination | 1 | 2022 | 241 | 0.040 |
Why?
| | Health Maintenance Organizations | 1 | 2000 | 108 | 0.040 |
Why?
| | Community-Based Participatory Research | 1 | 2021 | 162 | 0.040 |
Why?
| | Needs Assessment | 1 | 2022 | 376 | 0.040 |
Why?
| | Focus Groups | 1 | 2022 | 522 | 0.040 |
Why?
| | Clinical Clerkship | 1 | 2000 | 101 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 117 | 0.040 |
Why?
| | Radioimmunoassay | 1 | 1998 | 173 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1998 | 59 | 0.040 |
Why?
| | Risk | 1 | 2000 | 912 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 86 | 0.030 |
Why?
| | Odds Ratio | 1 | 2000 | 1070 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2057 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 183 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 294 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 827 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 786 | 0.030 |
Why?
| | Leptin | 1 | 1998 | 236 | 0.030 |
Why?
| | Models, Statistical | 1 | 2000 | 669 | 0.030 |
Why?
| | Peptides | 2 | 2015 | 985 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1066 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2000 | 548 | 0.030 |
Why?
| | Facial Muscles | 1 | 2015 | 5 | 0.030 |
Why?
| | Students, Medical | 1 | 2000 | 348 | 0.030 |
Why?
| | Cheek | 1 | 2015 | 17 | 0.030 |
Why?
| | Subcutaneous Tissue | 1 | 2015 | 24 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1266 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2000 | 2031 | 0.030 |
Why?
| | Eyelids | 1 | 2015 | 37 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 1996 | 259 | 0.030 |
Why?
| | Collagen Type III | 1 | 2013 | 16 | 0.030 |
Why?
| | Body Composition | 1 | 1998 | 684 | 0.030 |
Why?
| | Matrix Metalloproteinases | 1 | 2013 | 95 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 578 | 0.030 |
Why?
| | Isometric Contraction | 1 | 2013 | 188 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 752 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2015 | 635 | 0.020 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 15 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 431 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 852 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 530 | 0.020 |
Why?
| | Urban Health | 1 | 2010 | 92 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1353 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 5131 | 0.020 |
Why?
| | Hepacivirus | 1 | 2010 | 261 | 0.020 |
Why?
| | Bone Resorption | 1 | 2007 | 86 | 0.020 |
Why?
| | Area Under Curve | 1 | 2007 | 314 | 0.020 |
Why?
| | Hip Fractures | 1 | 2007 | 86 | 0.020 |
Why?
| | Inflammation | 1 | 2015 | 2837 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 21513 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2734 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9465 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11074 | 0.010 |
Why?
| | Massachusetts | 1 | 2000 | 172 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3295 | 0.010 |
Why?
| | Teaching | 1 | 2000 | 224 | 0.010 |
Why?
| | Risk Assessment | 1 | 2007 | 3457 | 0.010 |
Why?
| | Child | 1 | 2015 | 21935 | 0.010 |
Why?
| | Primary Health Care | 1 | 2000 | 1738 | 0.000 |
Why?
|
|
Christiansen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|